Methods and compositions for treating cancer

1. An immunogenic composition comprising:

(a) an adenoviral vector comprising a first expression cassette comprising a first nucleic acid sequence encoding a tumor-specific antigen fused within or to a protein that inhibits an immunoinhibitory pathway operatively linked to an expression control sequence that directs the expression of the fused antigen in a mammalian host cell; and

(b) an adenoviral vector comprising a second expression cassette comprising a second nucleic acid sequence encoding fibroblast activation protein (FAP) operatively linked to an expression control sequence directing the expression of FAP in a mammalian host cell,

said vectors in a pharmaceutically acceptable carrier suitable for administration to a mammal, and

wherein the inhibiting protein is HSV gD, or an antibody or fragment of antibody to PD-1, PD-L1, LAG-1 CTLA-4, BTLA, or CD160.

2. The composition according to claim 1 , wherein vector (a) and vector (b) are the same vector, wherein the fused antigen of (a) and FAP of (b) are presented as a fusion protein or wherein the fused antigen of (a) and FAP encoding sequences are linked by a splice site, or wherein the fused antigen of (a) and FAP encoding sequences are in two separate expression cassettes in a single vector.

3. The composition according to claim 1 , wherein the tumor-specific antigen of (a) is derived from a cancer that is a melanoma, breast cancer, colon cancer, prostate cancer, cervical cancer, ovarian cancer, or head and neck cancer.

4. The composition according to claim 1 , wherein the tumor antigen of (a) is a full-length tumor-specific antigen, a mutated tumor-specific antigen, a full-length or mutated tumor-associated antigen, or a polyepitope comprising a fusion of multiple tumor-specific or tumor-associated antigens.

5. The composition according to claim 4 , wherein the tumor-associated antigen of (a) is one or a multiple of different CD4+ and CD8+ melanoma antigen derived T cell epitopes.

6. The composition according to claim 5 , wherein the melanoma antigen derived T cell epitope is a mammalian tyrosinase-related protein 1 (Trp-1) epitope or a tyrosinase-related protein 2 (Trp-2) epitope or a combination of multiple Trp-1 and Trp-2 epitopes.

7. The composition according to claim 1 , wherein vector (a) and vector (b) are the same adenovirus vector, wherein the antigen of (a) and FAP of (b) are presented as a fusion protein or wherein the antigen and FAP encoding sequences are linked by a splice site, or wherein the antigen and FAP encoding sequences are in two separate expression cassettes in a single vector.

8. The composition according to claim 1 , wherein vector (a) and vector (b) are independent vectors, each the same or a different adenovirus vector, and wherein the expression control sequences are the same or different for each vector.

9. An immunogenic composition comprising:

(a) an adenoviral vector comprising a nucleic acid sequence encoding a fusion protein in operative association with an expression control sequence directing the expression of the fusion protein in a mammalian host cell, wherein fusion protein comprises the polyepitope comprising hTrp-2 CD4-88 SEQ ID NO: 3, hTrp-2 CD4-237 SEQ ID NO: 4, hTrp-2 CD4-449SEQ ID NO: 5, hTrp-2 CD8-188 SEQ ID NO: 9, hTrp-2 CD8-343 SEQ ID NO: 10, hTrp-2 CD8-363 SEQ ID NO: 11, mTrp-1 CD8-455 SEQ ID NO: 6, mTrp-1 CD8-481 SEQ ID NO: 7, mTrp-1 CD8-522 SEQ ID NO: 8, human glycoprotein hgp100 CD8-25 SEQ ID NO: 12 and Braf-V 600 E CD8-59 SEQ ID NO: 13, the polyepitope fused within HSV-gD; and

(b) an adenoviral vector comprising a second expression cassette comprising a nucleic acid sequence encoding fibroblast activation protein (FAP) operatively linked to an expression control sequence directing the expression of FAP in a mammalian host cell.